| Placebo | Sarilumab 200 mg q2w |
---|
LDA achieved (n = 37) | LDA not achieved (n = 91) | LDA achieved (n = 72) | LDA not achieved (n = 59) |
---|
CRP |
Week 2 | 1.2 | −2.9 | −95.0**
| −83.5 |
Week 24 | −31.9**
| −4.2 | −96.9**
| −90.2 |
C1M |
Week 2 | 4.5 | 2.2 | −55.8*
| −45.1 |
Week 24 | −16.8*
| −4.3 | −65.7**
| −54.1 |
C2M |
Week 2 | 0 | 3.4 | 0*
| −14.3 |
Week 24 | 0 | 3.5 | 0 | −6.7 |
MMP-3 |
Week 2 | −2.0 | 2.3 | −7.2 | −3.3 |
Week 24 | −9.7 | 0.4 | −47.2 | −34.2 |
OPG |
Week 2 | −5.1 | 1.6 | −6.5*
| −0.9 |
Week 24 | −1.9 | −1.8 | −4.6 | 0.9 |
sRANKL |
Week 2 | −4.7 | −0.8 | −7.9 | −2.3 |
Week 24 | −16.2*
| −0.8 | −39.7 | −25.8 |
- Percent change from baseline in biomarkers transformed in rank was compared between responder and nonresponder patients at week 24 using an analysis of variance (ANOVA)-type method, with response, visit, and response-by-visit interaction as fixed effects, rank-transformed baseline biomarker value and rank-transformed baseline biomarker-value-by-visit interaction as fixed covariates, and assuming an unstructured covariance structure. The model was run separately by treatment group (sarilumab 200 mg q2w and placebo).
-
C1M collagen type I MMP-cleaved fragment, C2M collagen type II MMP-cleaved fragment, CRP C-reactive protein, DAS28-CRP 28-joint disease activity score by CRP, LDA low disease activity, MMP matrix metalloproteinase, MTX methotrexate, OPG osteoprotegerin, q2w every 2 weeks, sRANKL soluble receptor activator of nuclear factor-kB ligand. *Nominal p < 0.05 vs nonresponder. **Nominal p < 0.01 vs nonresponder